Schizophrenia Research
Volume 122, Issue 1 , Pages 43-52 , September 2010

18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls

  • Douglas S. Lehrer

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • Boonshoft Schizophrenia Center for Research, Innovation Center at Kettering Health Network, 3535 Southern Blvd, Kettering, OH 45429, USA
    • Corresponding Author InformationCorresponding author. Wright State University School of Medicine Boonshoft School of Medicine, Department of Psychiatry, East medical Plaza, 1st Floor, 627 S. Edwin C. Moses Blvd., Dayton, Ohio 45417, U.S.A. Tel.: +1 937 223 8840; fax +1 937 223 0758.
    • ,
  • Bradley T. Christian

      Affiliations

    • Waisman Laboratory for Brain Imaging, University of Wisconsin-Madison, 1500 Highland Avenue, Madison, WI, 53705, USA
    • ,
  • Cemil Kirbas

      Affiliations

    • Boonshoft Schizophrenia Center for Research, Innovation Center at Kettering Health Network, 3535 Southern Blvd, Kettering, OH 45429, USA
    • ,
  • Meicheng Chiang

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • ,
  • Shawn Sidhu

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • ,
  • Holly Short

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • ,
  • Binquan Wang

      Affiliations

    • Boonshoft Schizophrenia Center for Research, Innovation Center at Kettering Health Network, 3535 Southern Blvd, Kettering, OH 45429, USA
    • ,
  • Bingzhi Shi

      Affiliations

    • Boonshoft Schizophrenia Center for Research, Innovation Center at Kettering Health Network, 3535 Southern Blvd, Kettering, OH 45429, USA
    • ,
  • King-Wai Chu

      Affiliations

    • Weill Medical College of Cornell University, Imaging Data Evaluation and Analysis Laboratory (IDEAL), 425 East 61 Street, New York, NY 10065, USA
    • ,
  • Brian Merrill

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • ,
  • Monte S. Buchsbaum

      Affiliations

    • Wright State University Boonshoft School of Medicine, c/o Department of Psychiatry, East Medical Plaza,1st Floor, 627 South Edwin C. Moses Blvd., Dayton, OH 45408, USA
    • Boonshoft Schizophrenia Center for Research, Innovation Center at Kettering Health Network, 3535 Southern Blvd, Kettering, OH 45429, USA
    • Departments of Psychiatry and Radiology, University of California, San Diego, NeuroPET Center, 11388 Sorento Valley Road, Suite #100, San Diego, CA 92121; Department of Psychiatry and Human Behavior/University of California-Irvine (emeritus); Mount Sinai School of Medicine (adjunct), New York, USA

Received 24 November 2009 ,Revised 26 March 2010 ,Accepted 30 March 2010.

References 

  1. Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, et al. Striatal vs extrastriatal dopamine D-2 receptors in antipsychotic response — a double-blind PET study in schizophrenia. Neuropsychopharmacology. 2007;32:1209–1215
  2. Ahveninen J, Jaaskelainen IP, Raij T, Bonmassar G, Devore S, et al. Task-modulated “what” and “where” pathways in human auditory cortex. Proc. Natl. Acad. Sci. U. S. A. 2006;103:14608–14613
  3. Alelu-Paz R, Gimenez-Amaya JM. The mediodorsal thalamic nucleus and schizophrenia. J. Psychiatry Neurosci. 2008;33:489–498
  4. Andreasen NC, Carson R, Diksic M, Evans A, Farde L, et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum. Schizophr. Bull. 1988;14:471–484
  5. Andreasen NC, Oleary DS, Flaum M, Nopoulos P, Watkins GL, et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet. 1997;349:1730–1734
  6. Asselin MC, Montgomery AJ, Grasby PM, Hume SP. Quantification of PET studies with the very high-affinity dopamine D-2/D-3 receptor ligand [C-11]FLB 457: re-evaluation of the validity of using a cerebellar reference region. J. Cereb. Blood Flow Metab. 2007;27:378–392
  7. Bleich-Cohen M, Hendler T, Kotler M, Strous RD. Reduced language lateralization in first-episode schizophrenia: an fMRI index of functional asymmetry. Psychiatry Res. Neuroimaging. 2009;171:82–93
  8. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J. Nucl. Med. 1997;38:1614–1623
  9. Buchsbaum MS, Christian BT, Lehrer DS, Narayanan TK, Shi BZ, et al. D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 2006;85:232–244
  10. Christian BT, Vandehey NT, Fox AS, Murali D, Oakes TR, et al. The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. NeuroImage. 2009;44:1334–1344
  11. Comar D, Zarifian E, Verhas M, Soussaline F, Maziere M, et al. Brain distribution and kinetics of chlorpromazine-c-11 in schizophrenics - positron emission tomography studies. Psychiatry Res. 1979;1:23–29
  12. Cunningham VJ, Hume SP, Price GR, Ahier RG, Cremer JE, Jones AK. Compartmental analysis of diprenorphine binding to opiate receptors in the rat in vivo and its comparison with equilibrium data in vitro. J. Cereb. Blood Flow Metab. 1991;11:1–9
  13. Delforge J, Bottlaender M, Loc'h C, Guenther I, Fuseau C, et al. Quantitation of extrastriatal D2 receptors using a very high-affinity ligand (FLB 457) and the multi-injection approach. J. Cereb. Blood Flow Metab. 1999;19:533–546
  14. Eckelman WC, Kilbourn MR, Mathis CA. Specific to nonspecific binding in radiopharmaceutical studies: it's not so simple as it seems!. Nucl. Med. Biol. 2009;36:235–237
  15. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordstrom AL, et al. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch. Gen. Psychiatry. 1990;47:213–219
  16. Ford JM, Roach BJ, Jorgensen KW, Turner JA, Brown GG, et al. Tuning in to the voices: a multisite fMRI study of auditory hallucinations. Schizophr. Bull. 2009;35:58–66
  17. Garcia-Cabezas MA, Rico B, Sanchez-Gonzalez MA, Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. NeuroImage. 2007;34:965–984
  18. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum. Brain Mapp. 2005;25:60–69
  19. Glenthoj BY, Mackeprang T, Svarer C, Rasmussen H, Pinborg LH, et al. Frontal dopamine D-2/3 receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol. Psychiatry. 2006;60:621–629
  20. Goldsmith SK, Shapiro RM, Joyce JN. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. a postmortem study. Arch. Gen. Psychiatry. 1997;54:649–658
  21. Hazlett EA, Buchsbaum MS, Haznedar MM, Singer MB, Germans MK, et al. Prefrontal cortex glucose metabolism and startle eyeblink modification abnormalities in unmedicated schizophrenia patients. Psychophysiology. 1998;35:186–198
  22. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: version III-025EFThe final common pathway. Schizophr. Bull. 2009;35:549–562
  23. Ichise M, Toyama H, Innis RB, Carson RE. Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J. Cereb. Blood Flow Metab. 2002;22:1271–1281
  24. Ito H, Takahashi H, Arakawa R, Takano H, Suhara T. Normal database of dopaminergic neurotransmission system in human brain measured by positron emission tomography. NeuroImage. 2008;39:555–565
  25. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry. 2003;160:13–23
  26. Kegeles LS, Slifstein M, Frankle WG, Xu XY, Hackett E, et al. Dose-occupancy study of striatal and extrastriatal dopamine D-2 receptors by aripiprazole in schizophrenia with PET and [F-18] Fallypride. Neuropsychopharmacology. 2008;33:3111–3125
  27. Kegeles LS, Slifstein M, Xu X, Hackett E, Gil R, et al. D-2/D-3 receptor binding in striatal and extrastriatal regions in schizophrenia measured with [F-18]fallypride PET. In: 7th International Symposium on Functional Neuroreceptor Mapping of the Living Brain. Pittsburgh, PA: Academic Press Inc Elsevier Science; 2008;p. T52-T
  28. Kessler RM, Mason NS, Votaw JR, De Paulis T, Clanton JA, et al. Visualization of extrastriatal dopamine D2 receptors in the human brain. Eur. J. Pharmacol. 1992;223:105–107
  29. Kessler RM, Woodward ND, Riccardi P, Li R, Ansari MS, et al. Dopamine D-2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biol. Psychiatry. 2009;65:1024–1031
  30. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. Distribution volume ratios without blood sampling from graphical analysis of PET data. J. Cereb. Blood Flow Metab. 1996;16:834–840
  31. Miller J, Williamson P, Jensen JE, Manchanda R, Menon R, et al. Longitudinal 4.0Tesla P-31 magnetic resonance spectroscopy changes in the anterior cingulate and left thalamus in first episode schizophrenia. Psychiatry Res NeuroImaging. 2009;173:155–157
  32. Mitelman SA, Shihabuddin L, Brickman AM, Hazlett EA, Buchsbaum MS. MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. Am. J. Psychiatry. 2003;160:2154–2168
  33. Mitelman SA, Brickman AM, Shihabuddin L, Newmark R, Chu KW, Buchsbaum MS. Correlations between MRI-assessed volumes of the thalamus and cortical Brodmann's areas in schizophrenia. Schizophr. Res. 2005;75:265–281
  34. Mitelman SA, Buchsbaum MS, Brickman AM, Shihabuddin L. Cortical intercorrelations of frontal area volumes in schizophrenia. NeuroImage. 2005;27:753–770
  35. Mukherjee J, Yang ZY, Das MK, Brown T. Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3-[18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nucl. Med. Biol. 1995;22:283–296
  36. Mukherjee J, Yang ZY, Brown T, Lew R, Wernick M, et al. Preliminary assessment of extrastriatal dopamine D-2 receptor binding in the rodent and nonhuman primate brains using the high affinity radioligand, 18F-fallypride. Nucl. Med. Biol. 1999;26:519–527
  37. Mukherjee J, Christian BT, Dunigan KA, Shi BZ, Narayanan TK, et al. Brain imaging of F-18-fallypride in normal volunteers: Blood analysis, distribution, test-retest studies, and preliminary assessment of sensitivity to aging effects on dopamine D-2/D-3 receptors. Synapse. 2002;46:170–188
  38. O'Daly OG, Frangou S, Chitnis X, Shergill SS. Brain structural changes in schizophrenia patients with persistent hallucinations. Psychiatry Res. Neuroimaging. 2007;156:15–21
  39. Oertel V, Rotarska-Jagiela A, van de Ven V, Haenschel C, Grube M, et al. Mental imagery vividness as a trait marker across the schizophrenia spectrum. Psychiatry Res. 2009;167:1–11
  40. Olsson H, Halldin C, Swahn CG, Farde L. Quantification of [11C]FLB 457 binding to extrastriatal dopamine receptors in the human brain. J. Cereb. Blood Flow Metab. 1999;19:1164–1173
  41. Olsson H, Halldin C, Farde L. Differentiation of extrastriatal dopamine D2 receptor density and affinity in the human brain using PET. NeuroImage. 2004;22:794–803
  42. Parellada E, Lomena F, Font M, Pareto D, Gutierrez F, et al. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation. Nucl. Med. Commun. 2008;29:894–900
  43. Perry R, Oakley A, Perry E. Coronal brain map and dissection guide: localization of Brodmann areas in coronal sections. New York, NY: Mt. Sinai School of Medicine; 1996;
  44. Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, Friberg L, et al. [I-123]epidepride binding to cerebellar dopamine D-2/D-3 receptors is displaceable: implications for the use of cerebellum as a reference region. NeuroImage. 2007;34:1450–1453
  45. Riccardi P, Li R, Ansari MS, Zald D, Park S, et al. Amphetamine-induced displacement of [F-18] fallypride in striatum and extrastriatal regions in humans. Neuropsychopharmacology. 2006;31:1016–1026
  46. Seok JH, Park HJ, Chun HW, Lee SK, Cho HS, et al. White matter abnormalities associated with auditory hallucinations in schizophrenia: A combined study of voxel-based analyses of diffusion tensor imaging and structural magnetic resonance imaging. Psychiatry Res. Neuroimaging. 2007;156:93–104
  47. Simeon D, Guralnik O, Hazlett EA, Spiegel-Cohen J, Hollander E, Buchsbaum MS. Feeling unreal: a PET study of depersonalization disorder. Am. J. Psychiatry. 2000;157:1782-+
  48. Stein DJ, Buchsbaum MS, Hof PR, Siegel BV, Shihabuddin L. Greater metabolic rate decreases in hippocampal formation and proisocortex than in neocortex in Alzheimer's disease. Neuropsychobiology. 1998;37:10–19
  49. Takahashi H, Higuchi M, Suhara T. The role of extrastriatal dopamine D2 receptors in schizophrenia. Biol. Psychiatry. 2006;59:919–928
  50. Talvik M, Nordstrom AL, Olsson H, Halldin C, Farde L. Decreased thalamic D-2/D-3 receptor binding in drug-naive patients with schizophrenia: a PET study with [C-11]FLB 457. Int. J. Neuropsychopharmacol. 2003;6:361–370
  51. Talvik M, Nordstrom AL, Okubo Y, Olsson H, Borg J, et al. Dopamine D-2 receptor binding in dirug-naive patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. NeuroImaging. 2006;148:165–173
  52. Tune LE, Wong DF, Pearlson G, Strauss M, Young T, et al. Dopamine D-2 receptor density estimates in schizophrenia - a positron emission tomography study with C-11 n-methylspiperone. Psychiatry Res. 1993;49:219–237
  53. Tuppurainen H, Kuikka J, Viinamaki H, Husso-Saastamoinen M, Bergstrom K, Tiihonen J. Extrastriatal dopamine D-2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry. 2003;8:453–455
  54. Tuppurainen H, Kuikka JT, Laakso MP, Viinamaki H, Husso M, Tiihonen J. Midbrain dopamine D-2/3 receptor binding in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2006;256:382–387
  55. van Haren NE, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RC, et al. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology. 2007;32:2057–2066
  56. Venkatasubramanian G. Neuroanatomical correlates of psychopathology in antipsychotic-naive schizophrenia. Indian J. Psychiatry. 2010;52:28–36
  57. Vilkman H, Kajander J, Nagren K, Oikonen V, Syvalahti E, Hietala J. Measurement of extrastriatal D-2-like receptor binding with [C-11]FLB 457 — a test-retest analysis. Eur. J. Nucl. Med. 2000;27:1666–1673
  58. Wong DF, Wagner HN, Tune LE, Dannals RF, Pearlson GD, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986;234:1558–1563
  59. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J. Comput. Assist. Tomogr. 1992;16:620–633
  60. Yasuno F, Suhara T, Okubo Y, Sudo Y, Inoue M, et al. Low dopamine D-2 receptor binding in subregions of the thalamus in schizophrenia. Am. J. Psychiatry. 2004;161:1016–1022
  61. Yasuno F, Suhara T, Okubo Y, Ichimiya T, Takano A, et al. Abnormal effective connectivity of dopamine D2 receptor binding in schizophrenia. Psychiatry Res. NeuroImaging. 2005;138:197–207
  62. Young KA, Randall PK, Wilcox RE. Startle and sensorimotor correlates of ventral thalamic dopamine and GABA in rodents. NeuroReport. 1995;6:2495–2499

PII: S0920-9964(10)01223-5

doi: 10.1016/j.schres.2010.03.043

Schizophrenia Research
Volume 122, Issue 1 , Pages 43-52 , September 2010

Article Tools

* Image Usage & Resolution